Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]P16-093 PET/CT in Prostate and Renal Cancer
NCT03073395Phase 1Completed
- Sponsor
- Five Eleven Pharma, Inc.
- Start
- Jul 2017
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-P16-093 in prostate cancer (PCa) and renal cell carcinoma (RCC) (2 arms), sponsored by Five Eleven Pharma, Inc. Primary endpoints: Uptake of [68Ga]P16-093 in metastatic prostate and renal cancer and Radiation dosimetry of [68Ga]P16-093. Started Jul 2017; status: completed.
02
Drugs
68Ga-P16-093
03
Conditions
prostate cancer (PCa)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03073395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03073395.